Literature DB >> 26553749

Dysregulation of miR-212 Promotes Castration Resistance through hnRNPH1-Mediated Regulation of AR and AR-V7: Implications for Racial Disparity of Prostate Cancer.

Yijun Yang1, Dingwu Jia1, Hogyoung Kim1, Zakaria Y Abd Elmageed1, Amrita Datta1, Rodney Davis1, Sudesh Srivastav2, Krzysztof Moroz3, Byron E Crawford4, Krishnarao Moparty5, Raju Thomas6, Robert S Hudson7, Stefan Ambs7, Asim B Abdel-Mageed8.   

Abstract

PURPOSE: The causes of disproportionate incidence and mortality of prostate cancer among African Americans (AA) remain elusive. The purpose of this study was to investigate the mechanistic role and assess clinical utility of the splicing factor heterogeneous nuclear ribonucleoprotein H1 (hnRNP H1) in prostate cancer progression among AA men. EXPERIMENTAL
DESIGN: We employed an unbiased functional genomics approach coupled with suppressive subtractive hybridization (SSH) and custom cDNA microarrays to identify differentially expressed genes in microdissected tumors procured from age- and tumor grade-matched AA and Caucasian American (CA) men. Validation analysis was performed in independent cohorts and tissue microarrays. The underlying mechanisms of hnRNPH1 regulation and its impact on androgen receptor (AR) expression and tumor progression were explored.
RESULTS: Aberrant coexpression of AR and hnRNPH1 and downregulation of miR-212 were detected in prostate tumors and correlate with disease progression in AA men compared with CA men. Ectopic expression of miR-212 mimics downregulated hnRNPH1 transcripts, which in turn reduced expression of AR and its splice variant AR-V7 (or AR3) in prostate cancer cells. hnRNPH1 physically interacts with AR and steroid receptor coactivator-3 (SRC-3) and primes activation of androgen-regulated genes in a ligand-dependent and independent manner. siRNA silencing of hnRNPH1 sensitized prostate cancer cells to bicalutamide and inhibited prostate tumorigenesis in vivo
CONCLUSIONS: Our findings define novel roles for hnRNPH1 as a putative oncogene, splicing factor, and an auxiliary AR coregulator. Targeted disruption of the hnRNPH1-AR axis may have therapeutic implications to improve clinical outcomes in patients with advanced prostate cancer, especially among AA men. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26553749      PMCID: PMC7472565          DOI: 10.1158/1078-0432.CCR-15-1606

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Androgen receptor localisation and turnover in human prostate epithelium treated with the antiandrogen, casodex.

Authors:  A S Waller; R M Sharrard; P Berthon; N J Maitland
Journal:  J Mol Endocrinol       Date:  2000-06       Impact factor: 5.098

Review 2.  Expression and function of androgen receptor coactivators in prostate cancer.

Authors:  Zoran Culig; Barbara Comuzzi; Hannes Steiner; Georg Bartsch; Alfred Hobisch
Journal:  J Steroid Biochem Mol Biol       Date:  2004-12-19       Impact factor: 4.292

3.  Binding of hnRNP H to an exonic splicing silencer is involved in the regulation of alternative splicing of the rat beta-tropomyosin gene.

Authors:  C D Chen; R Kobayashi; D M Helfman
Journal:  Genes Dev       Date:  1999-03-01       Impact factor: 11.361

Review 4.  Nuclear structure as a source of cancer specific biomarkers.

Authors:  Eddy S Leman; Robert H Getzenberg
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

5.  Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.

Authors:  Myles C Hodgson; Inna Astapova; Anthony N Hollenberg; Steven P Balk
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

Review 6.  Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex.

Authors:  Hannelore V Heemers; Donald J Tindall
Journal:  Endocr Rev       Date:  2007-10-16       Impact factor: 19.871

7.  hnRNP H1 and intronic G runs in the splicing control of the human rpL3 gene.

Authors:  Annapina Russo; Gabriella Siciliano; Morena Catillo; Chiara Giangrande; Angela Amoresano; Pietro Pucci; Concetta Pietropaolo; Giulia Russo
Journal:  Biochim Biophys Acta       Date:  2010-01-25

8.  Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins.

Authors:  Paola Barboro; Cristina D'Arrigo; Erica Repaci; Luca Bagnasco; Paola Orecchia; Barbara Carnemolla; Eligio Patrone; Cecilia Balbi
Journal:  Exp Cell Res       Date:  2008-10-28       Impact factor: 3.905

9.  Heterogeneous nuclear ribonucleoproteins F and H/H' show differential expression in normal and selected cancer tissues.

Authors:  Bent Honoré; Ulrik Baandrup; Henrik Vorum
Journal:  Exp Cell Res       Date:  2004-03-10       Impact factor: 3.905

10.  HnRNP-A1 binds directly to double-stranded DNA in vitro within a 36 bp sequence.

Authors:  Rossen M Donev; Teodora A Doneva; W Richard Bowen; Denise Sheer
Journal:  Mol Cell Biochem       Date:  2002-04       Impact factor: 3.842

View more
  34 in total

Review 1.  Epigenetic basis of cancer health disparities: Looking beyond genetic differences.

Authors:  Aamir Ahmad; Shafquat Azim; Haseeb Zubair; Mohammad Aslam Khan; Seema Singh; James E Carter; Rodney P Rocconi; Ajay P Singh
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-17       Impact factor: 10.680

Review 2.  MicroRNAs in prostate cancer: From function to biomarker discovery.

Authors:  Ahmed A Moustafa; Hogyoung Kim; Rasha S Albeltagy; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2018-06

3.  Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling and hnRNP H1 in castration-resistant prostate cancer cells.

Authors:  Amrita Datta; Hogyoung Kim; Madhu Lal; Lauren McGee; Adedoyin Johnson; Ahmed A Moustafa; Jennifer C Jones; Debasis Mondal; Marc Ferrer; Asim B Abdel-Mageed
Journal:  Cancer Lett       Date:  2017-08-24       Impact factor: 8.679

4.  HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.

Authors:  Yanfeng Li; Jesse Bakke; David Finkelstein; Hu Zeng; Jing Wu; Taosheng Chen
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

5.  Identification of microRNA signature and potential pathway targets in prostate cancer.

Authors:  Ahmed A Moustafa; Mohammed Ziada; Abubaker Elshaikh; Amrita Datta; Hogyoung Kim; Krzysztof Moroz; Sudesh Srivastav; Raju Thomas; Jonathan L Silberstein; Krishnarao Moparty; Fatma Elzahraa H Salem; Ola H El-Habit; Asim B Abdel-Mageed
Journal:  Exp Biol Med (Maywood)       Date:  2016-12-08

Review 6.  Human antigen R and drug resistance in tumors.

Authors:  Fenghai Zhou; Fa Zhang; Chuan Zhou; Mengtian Liang; Zhonglin Cai; Haidi Lv; Wenjuan Li; Xupan Wei
Journal:  Invest New Drugs       Date:  2019-01-05       Impact factor: 3.850

7.  A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.

Authors:  Jacqueline Olender; Bi-Dar Wang; Travers Ching; Lana X Garmire; Kaitlin Garofano; Youngmi Ji; Tessa Knox; Patricia Latham; Kenneth Nguyen; Johng Rhim; Norman H Lee
Journal:  Mol Cancer Res       Date:  2019-07-02       Impact factor: 5.852

Review 8.  Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.

Authors:  E S Antonarakis; A J Armstrong; S M Dehm; J Luo
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-05-17       Impact factor: 5.554

9.  Androgen receptor variants: RNA-based mechanisms and therapeutic targets.

Authors:  Kiel T Tietz; Scott M Dehm
Journal:  Hum Mol Genet       Date:  2020-09-30       Impact factor: 6.150

10.  Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity.

Authors:  Bethtrice Elliott; DeAdra L Zackery; Vanessa A Eaton; Re'Josef T Jones; Fisseha Abebe; Camille C Ragin; Shafiq A Khan
Journal:  Carcinogenesis       Date:  2018-04-05       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.